216 related articles for article (PubMed ID: 33384601)
1. Role of PRDM1 in Tumor Immunity and Drug Response: A Pan-Cancer Analysis.
Shen L; Chen Q; Yang C; Wu Y; Yuan H; Chen S; Ou S; Jiang Y; Huang T; Ke L; Mo J; Feng Z; Zhou P; Fan W
Front Pharmacol; 2020; 11():593195. PubMed ID: 33384601
[No Abstract] [Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of zinc and ring finger 3 in prognostic value and pan-cancer immunity.
Liu M; Zhao H; Peng S; Wu Y; Liu Y; Sun W; Zen K; Sun X
FASEB J; 2024 Mar; 38(5):e23523. PubMed ID: 38457275
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
5. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
Wen J; Mao X; Cheng Q; Liu Z; Liu F
Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
[TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis.
Liu Y; Xue J; Zhong M; Wang Z; Li J; Zhu Y
Front Mol Biosci; 2021; 8():692120. PubMed ID: 34395525
[No Abstract] [Full Text] [Related]
8. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
9. Role of CD47 in tumor immunity: a potential target for combination therapy.
Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancers.
Tang X; Sui X; Liu Y
Heliyon; 2023 Jan; 9(1):e12873. PubMed ID: 36685446
[TBL] [Abstract][Full Text] [Related]
11. PreMSIm: An R package for predicting microsatellite instability from the expression profiling of a gene panel in cancer.
Li L; Feng Q; Wang X
Comput Struct Biotechnol J; 2020; 18():668-675. PubMed ID: 32257050
[TBL] [Abstract][Full Text] [Related]
12. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
13. Integrative omics analysis reveals relationships of genes with synthetic lethal interactions through a pan-cancer analysis.
Guo L; Li S; Qian B; Wang Y; Duan R; Jiang W; Kang Y; Dou Y; Yang G; Shen L; Wang J; Liang T
Comput Struct Biotechnol J; 2020; 18():3243-3254. PubMed ID: 33240468
[TBL] [Abstract][Full Text] [Related]
14. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
16. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
17. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts.
Zeng Z; Gao Y; Li J; Zhang G; Sun S; Wu Q; Gong Y; Xie C
Comput Struct Biotechnol J; 2022; 20():496-507. PubMed ID: 35070171
[TBL] [Abstract][Full Text] [Related]
18. The SARS-CoV-2 host cell receptor ACE2 correlates positively with immunotherapy response and is a potential protective factor for cancer progression.
Zhang Z; Li L; Li M; Wang X
Comput Struct Biotechnol J; 2020; 18():2438-2444. PubMed ID: 32905022
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of the novel omicron receptor AXL in cancers.
Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.
Liu S; Yang L; Fu J; Li T; Zhou B; Wang K; Wei C; Fu J
Front Immunol; 2023; 14():1149986. PubMed ID: 37020558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]